Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine
Science·
- DOI
- 10.1126/science.aba1238
- PMID
- 32193361
- PMCID
- PMC10805349
- OpenAlex
- W3012245583
- Study type
- Journal article
- Publisher
- American Association for the Advancement of Science (AAAS)
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The findings are framed around the threat that circulating VDPV2 poses to polio eradication and the need for a new oral polio vaccine together with a contingency strategy, given that current outbreak response tools may themselves contribute to ongoing transmission.
Structured evidence summary
Research question
This work examines how serotype 2 vaccine-derived poliovirus has continued to emerge after the global withdrawal of the oral poliovirus vaccine serotype 2 component, and what this implies for outbreak response strategies.
Study design
A statistical model was used to estimate the emergence dates and sources of serotype 2 vaccine-derived polioviruses detected during a defined surveillance window.
Population and setting
The study covers serotype 2 vaccine-derived polioviruses detected globally between May 2016 and November 2019, spanning multiple continents, with a focus on populations whose immunity to serotype 2 is limited following the April 2016 OPV2 withdrawal.
Main findings
The authors report continued detection of serotype 2 vaccine-derived poliovirus and associated paralytic cases across several continents after OPV2 withdrawal. Their analysis indicates that monovalent OPV2 outbreak response campaigns are themselves generating additional paralytic VDPV2 outbreaks with the potential to establish endemic transmission. Novel oral poliovirus vaccine type 2 candidates are described as still being in clinical trials at the time of writing.
Public-health relevance
The findings are framed around the threat that circulating VDPV2 poses to polio eradication and the need for a new oral polio vaccine together with a contingency strategy, given that current outbreak response tools may themselves contribute to ongoing transmission.
Important limitations
The article does not state explicit limitations within the abstract. This summary is limited to the supplied single-article abstract and bibliographic metadata and requires consultation of the original paper, including model assumptions and the May 2016–November 2019 detection window, before decision-grade interpretation.
GIDS interpretation
Within GIDS, this article is discoverable as a peer-reviewed epidemiological study addressing vaccination, outbreak response, and transmission dynamics for poliovirus serotype 2. Any connection to a live surveillance signal would require separate verification beyond the supplied evidence.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 11 auditable classifier relationships to diseases, places, topics, and study design.